Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia
Autore:
Tunis, SL; Johnstone, BM; Gibson, PJ; Loosbrock, DL; Dulisse, BK;
Indirizzi:
Lilly Corp Ctr, Lilly Res Labs, Lilly USA, Hlth Outcomes Evaluat Grp, Indianapolis, IN 46285 USA Lilly Corp Ctr Indianapolis IN USA 46285 Grp, Indianapolis, IN 46285 USA Indiana Univ, Sch Med, Indianapolis, IN USA Indiana Univ Indianapolis IN USA ana Univ, Sch Med, Indianapolis, IN USA Indiana Univ, Sch Publ & Environm Affairs, Bloomington, IN USA Indiana Univ Bloomington IN USA & Environm Affairs, Bloomington, IN USA Eli Lilly & Co, Lilly Res Labs, Stat & Math Sci, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 Sci, Indianapolis, IN 46285 USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
, volume: 60, anno: 1999, supplemento:, 19
pagine: 38 - 45
SICI:
0160-6689(1999)60:<38:CIPHAF>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
QUALITY-OF-LIFE; NEGATIVE SYNDROME SCALE; DOUBLE-BLIND; SURVEY SF-36; MEDICAL COMORBIDITY; SERVICES RESEARCH; WORK PERFORMANCE; MENTALLY-ILL; SYMPTOMS; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
74
Recensione:
Indirizzi per estratti:
Indirizzo: Tunis, SL Lilly Corp Ctr, Lilly Res Labs, Lilly USA, Hlth Outcomes EvaluatGrp, DropCode 1850, Indianapolis, IN 46285 USA Lilly Corp Ctr Drop Code 1850 Indianapolis IN USA 46285 6285 USA
Citazione:
S.L. Tunis et al., "Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia", J CLIN PSY, 60, 1999, pp. 38-45

Abstract

We utilize data from a large, double-blind, randomized clinical trial of treatment for schizophrenia to compare the effect of therapy with the secondgeneration antipsychotic olanzapine versus therapy with the conventional agent haloperidol on the perceived functioning and well-being of patients over 1 year as measured by the Medical Outcome Study Shea Form (SF-36). We also compare the total cost of care between the treatment groups over 1 year and combine cost and functional outcomes information to estimate the incremental cost-effectiveness of both therapies in this sample. Over I year of therapy, patients receiving olanzapine experienced a mean of 5.75 units greater improvement than did haloperidol-treated patients on the physical health and functioning factor of the SF-36 and 1.66 units greater improvement onthe mental health and functioning factor. The mean annual total cost of care, including the cost of medication therapies, was $9386.87 less for olanzapine-treated patients than for haloperidol-treated patients. The incremental cost-effectiveness ratio for olanzapine versus haloperidol treatment indicated a savings of $1632.50 per unit of improvement in the SF-36 physical health and functioning score and a savings of $5654.74 per unit of improvement in the mental health and functioning composite. Improvements in perceived health and functioning were also associated with reduction in hospital costs in the full sample. These findings suggest that patient-centered measures of functioning such as the SF-36 are an important component of the evaluation of the cost-effectiveness of novel treatments for schizophrenia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/07/20 alle ore 07:41:24